GH Research (GHRS) Depreciation & Amortization (CF) (2021 - 2025)
GH Research (GHRS) recorded quarterly Depreciation & Amortization (CF) of $88000.0 in Q4 2025, down 1.12% quarter-over-quarter from $89000.0 in Q3 2025, and up 54.39% on a YoY basis from $57000.0 in Q4 2024.
GH Research (GHRS) Depreciation & Amortization (CF) (2021 - 2025) Analysis & Trends
GH Research's Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $88000.0 for Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) rose 54.39% year-over-year to $88000.0; the TTM figure through Dec 2025 stood at $335000.0 (up 13.95% YoY), while the FY2025 annual figure was $335000.0, up 13.95% from the prior year.
- Depreciation & Amortization (CF) was $88000.0 for Q4 2025 at GH Research, down from $89000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $89000.0 in Q3 2025 to a low of $1000.0 in Q1 2021.
- Historically, Depreciation & Amortization (CF) has averaged $50500.0 across 5 years, with a median of $76500.0 in 2023.
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) jumped 1000.0% in 2022, then dropped 26.92% in 2024.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $9000.0 in 2021, then soared by 44.44% to $13000.0 in 2022, then jumped by 500.0% to $78000.0 in 2023, then declined by 26.92% to $57000.0 in 2024, then surged by 54.39% to $88000.0 in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $88000.0 (Q4 2025), $89000.0 (Q3 2025), and $82000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 1,395.22 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 429,663.65 |
| 10 | GH Research | 9.73 Bn | 9.63 Bn | - | 88,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 88,000.00 |
| Dec 31, 2025 | 88,000.00 |
| Sep 30, 2025 | 89,000.00 |
| Sep 30, 2025 | 89,000.00 |
| Jun 30, 2025 | 82,000.00 |
| Jun 30, 2025 | 82,000.00 |
| Mar 31, 2025 | 76,000.00 |
| Mar 31, 2025 | 76,000.00 |
| Dec 31, 2024 | 57,000.00 |
| Dec 31, 2024 | 57,000.00 |
| Sep 30, 2024 | 79,000.00 |
| Sep 30, 2024 | 79,000.00 |
| Jun 30, 2024 | 78,000.00 |
| Jun 30, 2024 | 78,000.00 |
| Mar 31, 2024 | 80,000.00 |
| Mar 31, 2024 | 80,000.00 |
| Dec 31, 2023 | 78,000.00 |
| Dec 31, 2023 | 78,000.00 |
| Sep 30, 2023 | 80,000.00 |
| Sep 30, 2023 | 80,000.00 |